Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)
C. Wheeler et al., Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV), LEUK LYMPH, 40(5-6), 2001, pp. 499-509
Secondary malignancies, particularly myelodysplasia (MDS), are serious even
ts following high dose therapy with autologous stem cell support. We observ
ed a higher frequency of secondary malignancies in patients with Hodgkin's
disease (HD) than in patients with non-Hodgkin's lymphoma (NHL) undergoing
high dose therapy with the same non-TBI conditioning regimen. Three hundred
patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were
treated with cyclophosphamide. carmustine and etoposide and autologous ste
m cell support from 1986 through 1994. Median follow up of survivors is 3.9
years. Five-year survival is 51% for HD and 48% for NHL. Eleven patients d
eveloped second malignancies (9/150 treated for HD vs. 2/150 treated for NH
L) a median of 2.4 years from transplantation and 5.2 years from initial di
agnosis. Six patients had myelodysplasia or acute leukemia (MDS/AML) and 5
had lymphomas or solid tumors. Actuarial risk of MDS/AML at five years for
patients transplanted for non-Hodgkin's lymphoma is 3% (95 % CI 0.6-9.6%).
HD patients had significantly different pretreatment characteristics than p
atients with NHL. A Cox model showed that greater number of prior relapses
and prior radiation therapy were significant risk factors for the developme
nt of MDS/AML. These data suggest that CBV is associated with a lower risk
of secondary MDS/AML than TBI containing regimens and that much of the risk
is associated with thtr pre-transplantation therapy. The use of autotransp
lantation early in the course of therapy for relapsed lymphoma might preven
t some cases of MDS/AML.